The European Medicines Agency announced on Tuesday, May 4 the launch of a "
continuous review
" procedure for the Chinese Sinovac vaccine against Covid-19, which paves the way for a possible request for an upcoming authorization in the Union European.
Read also: Covid-19: the WHO investigation hampered by China
The decision of the Committee for Medicinal Products for Human Use of the EMA "
to start the continuous review is based on preliminary results of laboratory studies (non-clinical data) and clinical studies
", explains in a press release the European regulator based in Amsterdam.